Clinical trial
SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously…
NCT00006003 · National Cancer Institute (NCI), NIH · Terminated
Key facts
| NCT number | NCT00006003 |
|---|---|
| Title | SU5416 in Treating Patients With Metastatic Melanoma That Has Been Previously Treated |
| Official title | A Phase II Trial of SU5416 (NSC #696819) in Patients With Metastatic Melanoma |
| Lead sponsor | National Cancer Institute (NCI), NIH |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Recurrent Melanoma, Stage IV Melanoma |
| Intervention type | Drug, Other |
| Interventions | semaxanib, laboratory biomarker analysis |
| Enrollment | 35 |
| Start date | Jul 1, 2000 |
| Primary completion | Jul 1, 2003 |
| First posted | Jan 27, 2003 |
| Last update posted | Jan 24, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: